Welcome to our dedicated page for Rafael Holdings news (Ticker: RFL), a resource for investors and traders seeking the latest updates and insights on Rafael Holdings stock.
Rafael Holdings, Inc. (RFL) news coverage centers on its activities as a biotechnology company developing pharmaceuticals and managing a portfolio of clinical and early-stage life science and technology businesses. Company press releases highlight progress in its lead program, Trappsol® Cyclo™, an investigational therapy for Niemann-Pick Disease Type C1 (NPC1), as well as updates from its wholly owned subsidiary Cyclo Therapeutics, LLC.
Investors following RFL news can expect regular updates on the pivotal Phase 3 TransportNPC™ clinical trial and related sub-studies of Trappsol® Cyclo™, including interim analyses, Data Monitoring Committee recommendations and presentations of clinical data at scientific meetings. News items also describe regulatory interactions, such as acceptance of statistical analysis plans, and design details of the NPC1 and Alzheimer’s disease trials conducted by Cyclo Therapeutics.
Rafael Holdings’ releases further cover financial results for its fiscal quarters and year, including net loss figures, research and development spending, and the impact of consolidating subsidiaries such as Cyclo Therapeutics, Cornerstone and Day Three Labs. Capital markets activity is another recurring theme, with announcements about a $25 million rights offering of Class B common stock, the associated standby purchase agreement and the issuance and exchange of warrants in connection with the merger with Cyclo Therapeutics, Inc.
Governance and corporate developments also appear in the RFL news flow. Examples include board and management changes, such as the election of new directors, committee appointments, the passing of a lead independent director, and executive transitions including the appointment of a Chief Operating Officer. For readers tracking RFL, this news page provides a consolidated view of clinical, financial, governance and capital structure developments disclosed by Rafael Holdings.
Rafael Holdings (NYSE: RFL) announced a $5 million buyback of its Class B common stock to enhance shareholder value. CEO Bill Conkling emphasized the company's strong balance sheet and strategic opportunities in the current macroeconomic environment. The repurchase signals confidence in the company's long-term value creation strategy. The buyback will occur through open market purchases and other means, contingent upon market conditions and regulatory factors. Rafael Holdings aims to expand investments beyond biopharma, leveraging Executive Chairman Howard Jonas's expertise in identifying lucrative opportunities.
Rafael Holdings, Inc. (NYSE: RFL) reported its fiscal Q2 2023 results, highlighting a net loss of $3.3 million, or $0.13 per share, compared to a loss of $2.1 million, or $0.09 per share, in Q2 2022. As of January 31, 2023, the company had $88.9 million in cash, cash equivalents, and marketable securities. For the first half of fiscal 2023, Rafael recorded a net loss of $8.5 million, significantly reduced from $130.9 million in the prior year, which included substantial write-offs and impairments. R&D expenses decreased to $4.3 million from $5.5 million year-over-year, reflecting winding down programs at Barer Institute. General and administrative costs also declined. CEO Bill Conkling emphasized the strong balance sheet for funding pipeline assets.
Rafael Holdings, Inc. (NYSE: RFL) reported its first quarter fiscal 2023 results, reflecting significant progress. The company completed a successful real estate sale, generating $33 million in net proceeds. As of October 31, 2022, Rafael Holdings holds $93.8 million in cash and marketable securities. The net loss narrowed to $5.2 million ($0.22 per share) compared to a $128.9 million loss ($5.88 per share) in the prior year. R&D expenses remained stable at $2.1 million, while general and administrative expenses decreased to $3.1 million from $12.3 million, indicating improved cost management.
Rafael Holdings, Inc. (NYSE: RFL) announced on Nov. 15, 2022, a strategic shift to curtail early-stage development efforts, focusing instead on acquiring clinical stage assets to reduce spending. As of July 31, 2022, the company had $63.2 million in cash and received an additional $33 million from real estate sales. CEO Bill Conkling highlighted the company's strong balance sheet and opportunity for strategic business development amidst biotech sector dislocation, aiming for investments that address unmet medical needs and enhance shareholder value.
Rafael Holdings, Inc. (NYSE: RFL) reported its financial results for the three and twelve months ending July 31, 2022. The company had a net loss from continuing operations of $4.6 million, or $0.24 per share, for the quarter, down from a loss of $12.2 million last year. Revenue dropped to $0.07 million from $0.19 million year-over-year. For the full year, the net loss was $122.8 million, significantly higher than the previous year's $22.8 million. The company has cash and marketable securities totaling $63.2 million plus $33 million in proceeds from property sales to boost its business development efforts.
Cornerstone Pharmaceuticals has announced the initiation of a Phase 1 clinical trial for CPI-613 (devimistat), aimed at treating advanced pancreatic cancer. The trial, taking place at the Medical College of Wisconsin, will assess the safety and maximum tolerated dose of devimistat combined with gemcitabine and radiation therapy. With orphan drug designations from the FDA and EMA, devimistat targets cancer cell energy metabolism, potentially improving treatment outcomes in a disease known for high mortality rates.
Rafael Holdings, Inc. (NYSE: RFL) announced the completion of its building sale located at 520 Broad Street, Newark, for $49.4 million. After paying off a $15 million mortgage, the company expects net proceeds of approximately $33 million. Previously, Rafael Holdings reported cash and marketable securities of $59.4 million as of April 30, 2022, not including a recent $6 million raised through stock sales. CEO Bill Conkling emphasized that the sale strengthens the company’s balance sheet, enabling them to advance their early-stage cancer therapeutics pipeline.
Cornerstone Pharmaceuticals has successfully completed a Phase 1b clinical trial of its drug CPI-613® (devimistat) combined with gemcitabine and cisplatin for treating advanced biliary tract cancer. The trial involved 20 patients, achieving a 45% overall response rate and a median progression-free survival of 14.9 months. Seven patients are still receiving treatment. The Phase 2 trial is currently open, aiming to enroll 78 patients across 10 centers. Devimistat has been granted orphan drug designation by the FDA for multiple rare cancers, indicating its potential therapeutic importance.
Cornerstone Pharmaceuticals has appointed Dr. Jason Locasale to its Scientific Advisory Board. Dr. Locasale, an expert in cancer metabolism and metabolomics, is expected to enhance the company’s clinical programs and research on rare cancers. The company’s lead compound, CPI-613®, is under multiple clinical trials and has received orphan drug designations from both the FDA and EMA for several types of cancer. This appointment aims to strengthen the company’s ability to address the nutritional and metabolic challenges in cancer treatment.
Cornerstone Pharmaceuticals has announced the presentation of data from its open-label phase 1 study of CPI-613® (devimistat) combined with gemcitabine and nab-paclitaxel for locally advanced or metastatic pancreatic cancer. The results will be shared at the ESMO World Congress on Gastrointestinal Cancer 2022 from June 29 to July 2 in Barcelona, Spain. The study, involving 22 patients, demonstrated that devimistat is well tolerated and potentially synergistic with chemotherapy, paving the way for future treatment options for this prevalent and challenging cancer.